{"id":1387,"date":"2026-09-03T09:24:00","date_gmt":"2026-09-03T09:24:00","guid":{"rendered":"https:\/\/vistaralabs.ca\/cjc-1295-ipamorelin-human-studies\/"},"modified":"2026-09-04T08:24:58","modified_gmt":"2026-09-04T08:24:58","slug":"cjc-1295-ipamorelin-human-studies","status":"publish","type":"post","link":"https:\/\/vistaralabs.ca\/fr\/cjc-1295-ipamorelin-human-studies\/","title":{"rendered":"CJC-1295 + Ipamorelin: The Research"},"content":{"rendered":"<p><strong>Ipamorelin, the secretagogue half of the CJC-1295 + ipamorelin pairing, has a clean human pharmacology record \u2014 and an honest one, because not every trial hit its target.<\/strong> Two published studies tell both sides.<\/p>\n<h2>Findings<\/h2>\n<ul class=\"vl-findings\">\n<li>In the first study of ipamorelin, it produced a clear, <strong>dose-dependent release of growth hormone<\/strong>.<\/li>\n<li>Ipamorelin was selective: growth hormone rose without meaningful rises in stress or lactation hormones.<\/li>\n<li>In studies, CJC-1295 raised growth hormone and IGF-1, with effects lasting days after a single dose.<\/li>\n<li>The blend combines two different triggers of the same system, which is exactly why the pair is studied together.<\/li>\n<\/ul>\n<h2>The human PK study (Pharm Res, 1999)<\/h2>\n<p>Gobburu and colleagues ran a dose-escalation trial in healthy male volunteers, with eight subjects at each of five infusion rates. Ipamorelin induced growth-hormone release at every dose level, as a single episode peaking around 40 minutes and declining exponentially. The pharmacokinetics were dose-proportional, with a short 2-hour half-life. In plain terms: the compound does, measurably, what it is designed to do in humans.<\/p>\n<h2>The postoperative-ileus trial (Int J Colorectal Dis, 2014)<\/h2>\n<p>A multicenter, double-blind, placebo-controlled Phase 2 trial gave 114 bowel-resection patients intravenous ipamorelin or placebo twice daily. Ipamorelin was well tolerated, and median time to first tolerated meal was shorter (25.3 vs 32.6 hours), but the difference did not reach statistical significance (P=0.15). The honest reading: safe, promising direction, endpoint not met.<\/p>\n<h2>What CJC-1295 and ipamorelin are<\/h2>\n<p>The two are studied together because they hit the growth-hormone axis by different routes. CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue; ipamorelin is a ghrelin-receptor agonist, a growth-hormone secretagogue. Our <a href=\"https:\/\/vistaralabs.ca\/cjc-1295-ipamorelin-no-dac\/\">CJC-1295 + Ipamorelin (No-DAC) explainer<\/a> and our <a href=\"https:\/\/vistaralabs.ca\/cjc-1295-ipamorelin-vs-tesamorelin\/\">comparison with tesamorelin<\/a> cover the pairing.<\/p>\n<div class=\"vl-note\">\n<p>Vistara Labs stocks the <a href=\"https:\/\/vistaralabs.ca\/cjc-1295-ipamorelin-10mg\/\">CJC-1295 + Ipamorelin blend<\/a> as research vials, shipped from within Canada to every province.<\/p>\n<\/div>\n<h2>Frequently asked questions<\/h2>\n<h3>What does the data on ipamorelin show?<\/h3>\n<p>A human pharmacokinetic study in healthy volunteers showed ipamorelin reliably stimulates a single pulse of growth-hormone release at every dose tested, with dose-proportional kinetics and a short half-life of about 2 hours.<\/p>\n<h3>Did ipamorelin work in its surgical trial?<\/h3>\n<p>It was safe but did not beat placebo on the key endpoint. In a Phase 2 trial for postoperative ileus after bowel surgery, ipamorelin was well tolerated but showed no significant efficacy difference versus placebo on time to first tolerated meal.<\/p>\n<h3>Why are CJC-1295 and ipamorelin paired?<\/h3>\n<p>They act on the growth-hormone axis by complementary mechanisms \u2014 CJC-1295 as a GHRH analogue, ipamorelin as a ghrelin-receptor agonist (secretagogue) \u2014 which is why the research community studies them together.<\/p>\n<p class=\"vl-citation\"><em>Sources: Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999;16:1412-1416. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10496658\/\" rel=\"nofollow noopener\" target=\"_blank\">PMID 10496658<\/a>. Beck DE, et al. Ipamorelin for postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29:1527-1534. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25331030\/\" rel=\"nofollow noopener\" target=\"_blank\">PMID 25331030<\/a>.<\/em><\/p>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"FAQPage\", \"mainEntity\": [{\"@type\": \"Question\", \"name\": \"What does the data on ipamorelin show?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"A human pharmacokinetic study in healthy volunteers showed ipamorelin reliably stimulates a single pulse of growth-hormone release at every dose tested, with dose-proportional kinetics and a short half-life of about 2 hours.\"}}, {\"@type\": \"Question\", \"name\": \"Did ipamorelin work in its surgical trial?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"It was safe but did not beat placebo on the key endpoint. In a Phase 2 trial for postoperative ileus after bowel surgery, ipamorelin was well tolerated but showed no significant efficacy difference versus placebo on time to first tolerated meal.\"}}, {\"@type\": \"Question\", \"name\": \"Why are CJC-1295 and ipamorelin paired?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"They act on the growth-hormone axis by complementary mechanisms \\u2014 CJC-1295 as a GHRH analogue, ipamorelin as a ghrelin-receptor agonist (secretagogue) \\u2014 which is why the research community studies them together.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Human studies of ipamorelin confirm it reliably triggers growth-hormone release in volunteers, with dose-proportional kinetics. A clear-eyed look at what the trials found, and where one fell short.<\/p>","protected":false},"author":1,"featured_media":1269,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_vistara_fr_title":"","_vistara_fr_desc":"","_vl_research_product":36,"footnotes":""},"categories":[33],"tags":[],"vl_research_area":[41],"class_list":["post-1387","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptide-research"],"_links":{"self":[{"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/posts\/1387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/comments?post=1387"}],"version-history":[{"count":2,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/posts\/1387\/revisions"}],"predecessor-version":[{"id":1458,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/posts\/1387\/revisions\/1458"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/media\/1269"}],"wp:attachment":[{"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/media?parent=1387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/categories?post=1387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/tags?post=1387"},{"taxonomy":"vl_research_area","embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/vl_research_area?post=1387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}